Bet it would be easier to co-formulate Fovista with AGN's DARPin :)
No doubt it would be. In all seriousness, AGN could be a potential suitor for Ophthotech; back-of-the-eye diseases are a major hole in AGN’s portfolio, but it’s not from a lack of trying.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”